Remdesivir WHO Announcement of guidelines not recommended for inpatients November 20, 11:32
Regarding the antiviral drug remdesivir, which has been specially approved in Japan as a treatment for the new coronavirus, WHO = World Health Organization analyzed clinical trials around the world and found that "the important effect that leads to a reduction in mortality rate etc. "It was not", and published a guideline that administration to inpatients is not recommended.
On the 20th, WHO analyzed clinical trials of inpatients around the world using the antiviral drug remdesivir and published treatment guidelines.
According to it, "there was no significant effect" on the reduction in mortality, the need for mechanical ventilation, and the time it took to improve symptoms.
For this reason, WHO states that remdesivir is "not recommended for inpatients, regardless of mild or severe symptoms."
Gilead Sciences, the American pharmaceutical company that developed Remdesivir, hasn't responded officially, but WHO data was rigorously validated when WHO released preliminary results of its own clinical trials last month. He has not yet received the drug and has expressed concern that it is inconsistent with the efficacy previously shown in other clinical trials.
Regarding remdesivir, the US FDA = Food and Drug Administration approved the use in an emergency in May, and in response to this, Japan also approved the use as a special case, and in the United States last month, a therapeutic drug for the new coronavirus Is officially approved as.
Chief Cabinet Secretary Kato "Recognizing that the Ministry of Health, Labor and Welfare does not need to review approval"
At a press conference after the Cabinet meeting, Chief Cabinet Secretary Kato stated that the guidelines were "not proven to be ineffective for remdesivir, and that there is not enough evidence that remdesivir is effective. I have. "
In addition, "In Japan, with the emergency use permission in the United States, a certain degree of efficacy was confirmed from the results of multiple clinical trials, so special approval was given in May, and treatment using remdesivir is currently being performed. We are aware that the Ministry of Health, Labor and Welfare is currently aware that there is no particular need to review approval. "